Investors Re-Embrace Tobacco Stocks Amid Shift to Smoke-Free Products

Wall Street investors are reportedly increasing their holdings in tobacco stocks, reversing years of ethical divestment as companies aggressively pivot toward smoke-free alternatives. This strategic shift is blurring long-standing moral lines that previously led pension funds and endowments to blacklist cigarette makers.

Tobacco companies generating significant sales from non-combustible products are now earning premium stock market valuations from returning institutional capital, according to The Wall Street Journal. This trend has gained momentum following the U.S. Food and Drug Administration's (FDA) authorization for Philip Morris International to market 20 variants of its Zyn nicotine pouches as a less harmful alternative to traditional smoking. The FDA's decision on June 30 noted a reduced risk of lung cancer, stroke, and heart disease associated with the pouches, which do not contain tobacco.

This regulatory milestone prompted swift action from major investment banks. Morgan Stanley raised its price target for Philip Morris to $200, citing the anticipated rollout of Zyn Ultra and increasing confidence in the company's smoke-free growth potential. Bank of America also issued a positive outlook, setting its target at $209 based on the company's high-margin smokeless product execution.

Philip Morris currently derives approximately 41% of its sales from non-combustible products and trades at a significant premium compared to rivals still heavily reliant on traditional cigarettes. Meanwhile, British American Tobacco (BAT) is undergoing a transformation, reportedly planning to eliminate 9,000 global jobs, or nearly 19% of its workforce. This reduction includes outsourcing 3,500 roles and deploying artificial intelligence to automate back-office operations. BAT aims to achieve $800 million in annual savings by 2028 to fund its expansion into smokeless products.

Analysts remain optimistic about the sector. Barclays noted the significant scale of BAT's workforce reduction. Experts at Jefferies and UBS have reiterated buy ratings on BAT, joining a majority of analysts who view the stock favorably as the company seeks to double its share of the U.S. oral nicotine market. As the volume of combustible cigarette sales continues its long-term decline, the industry's rapid evolution is reshaping institutional investment strategies.